Is Antiphospholipid Syndrome Hereditary?

Antiphospholipid syndrome (APS) is not hereditary in the way a single-gene condition like sickle cell disease is passed from parent to child. Instead, it behaves like most autoimmune disorders: certain gene variants raise your susceptibility, but the disease itself requires additional triggers to develop. Researchers have identified a growing list of genetic markers tied to APS risk, and family studies consistently show that autoimmune conditions cluster in the relatives of people with the syndrome. Still, having a parent or sibling with APS does not mean you will get it, and genetics alone cannot explain who develops the disease.

What APS Actually Is

APS is an autoimmune condition in which the immune system produces antibodies that mistakenly target phospholipids and the proteins that bind to them. These antiphospholipid antibodies are not just bystanders; they actively drive the disease by switching on cells involved in clotting and inflammation. They activate the cells lining blood vessels, platelets, and certain white blood cells, and they alter the structure of blood clots in ways that make the clots denser and harder for the body to dissolve.¹ The result is an elevated risk of blood clots in veins and arteries, as well as pregnancy complications such as recurrent miscarriage, preeclampsia, and stillbirth.²

The antibodies most commonly involved target two proteins: beta-2-glycoprotein I and prothrombin. These antibodies are not only markers that doctors test for but also active contributors to the excessive clotting that defines APS.³ APS can appear on its own (primary APS) or alongside another autoimmune condition such as lupus (secondary APS). In both forms, the central question of what causes the immune system to go awry in the first place leads directly to genetics.

Family Patterns and the Case for a Genetic Component

One of the strongest pieces of evidence for a genetic contribution comes from family studies. Researchers have found that people diagnosed with either primary or secondary APS frequently have relatives with other autoimmune diseases, not just APS itself. A positive family history for autoimmune conditions is common in these patients, and researchers have interpreted this clustering as support for a shared genetic predisposition.⁴

But family history alone does not prove that APS is straightforwardly inherited. A telling observation came from a family with multiple members who persistently tested positive for the same antiphospholipid antibodies. Only one member, the proband, experienced recurrent blood clots. Three healthy siblings carried the antibodies for years without developing any thrombotic events.⁵ This is a critical distinction. The tendency to produce antiphospholipid antibodies can run in families, but producing the antibodies is not the same as having the disease. Something else, some combination of additional genetic variants or environmental exposures, has to tip a person over the edge into actual clinical APS.

The Genes Involved

APS is what geneticists call a polygenic disorder: many genes, each with a small effect, combine to influence susceptibility. No single “APS gene” has been found, and the genetic landscape is complex enough that researchers are still piecing together which variants matter most.⁶

The earliest genetic studies focused on the HLA region, a stretch of DNA that encodes proteins the immune system uses to distinguish self from non-self. Certain HLA class II alleles, particularly HLA-DR4, HLA-DR7, HLA-DRw53, and HLA-DQB1*0302, have been linked to the production of anticardiolipin antibodies, one of the hallmark antibody types in APS.⁷ These HLA associations carry risk for producing antiphospholipid antibodies regardless of whether a person has lupus, primary APS, or some other autoimmune condition, suggesting that the genetic push toward antibody production is somewhat independent of the downstream disease.

Mouse experiments have reinforced the HLA connection. When researchers immunized mice lacking the relevant immune molecules (MHC class II, the mouse equivalent of HLA class II), the animals produced far fewer antiphospholipid antibodies. Restoring specific human HLA variants in those mice partially or fully brought antibody production back, confirming that these genes directly influence how the immune system responds to beta-2-glycoprotein I, the main target of APS antibodies.⁸

Beyond HLA, genome-wide studies have identified two gene regions that reach the highest bar for statistical significance: STAT4 and C1D.⁹ STAT4 is involved in signaling within immune cells and has also been linked to lupus and rheumatoid arthritis, reinforcing the idea that many autoimmune diseases share overlapping genetic architecture. Another gene, IRF5, which helps regulate the inflammatory response, has also been associated with APS susceptibility.¹⁰ More recently, whole exome sequencing has started to reveal additional gene variants beyond the usual suspects, including genes involved in both immune regulation and the clotting process itself.¹¹

The picture that emerges is one of layered risk. Having certain HLA types may predispose you to make antiphospholipid antibodies. Variants in immune-signaling genes like STAT4 and IRF5 may amplify the autoimmune response. And variants in clotting-related genes may determine whether that immune misbehavior actually leads to a blood clot. Each gene adds a small push, but none is sufficient on its own.¹²

When Inherited Clotting Variants Overlap with APS

One of the more practically important genetic interactions involves factor V Leiden, a common inherited mutation in a clotting protein that independently raises the risk of venous blood clots. About five percent of people of European descent carry this variant. In people who also have antiphospholipid antibodies, carrying factor V Leiden appears to further increase the risk of thrombotic events. In patients with lupus, factor V Leiden was an independent risk factor for venous clots, with an odds ratio of about 5, meaning carriers had roughly five times the risk compared to non-carriers. Meanwhile, lupus anticoagulant, one of the key antiphospholipid antibodies, was independently associated with both venous and arterial clots, with odds ratios above 6 for each.¹³ When the two risk factors appeared together, the combined effect was greater than either alone.¹⁴

The prothrombin G20210A polymorphism, another inherited clotting variant, has similarly been flagged as an additional layer of risk in the context of APS.¹⁰ In children, the combination of multiple inherited thrombophilia markers alongside antiphospholipid antibodies was found in patients who experienced ischemic stroke, while none of the control subjects had such a combination.¹⁵ This underscores a recurring theme: APS risk is cumulative. Inheriting one thrombophilia variant does not cause APS, but it can set the stage for a more severe outcome if APS develops.

Environmental Triggers and Why Genes Are Not the Whole Story

If genetics were the full explanation, you would expect identical twins to almost always share the disease. But APS, like lupus and many other autoimmune conditions, clearly requires something beyond DNA. Infections are the most studied environmental trigger. The prevailing theory is molecular mimicry: certain microbes carry proteins that structurally resemble beta-2-glycoprotein I, the protein most commonly targeted by antiphospholipid antibodies. When the immune system mounts a response to the infection, it may accidentally learn to attack the body’s own beta-2-glycoprotein I. Bacteria implicated in this process include Streptococcus pyogenes, the spirochete that causes Lyme disease, and Mycobacterium tuberculosis.¹⁶

This helps explain why some genetically predisposed individuals never develop APS. Without the right environmental spark, the genetic kindling stays unlit. It also helps explain why APS can sometimes appear abruptly after an infection, even in someone with no family history of autoimmune disease.

Epigenetic Changes in APS

Between genetics and environment sits epigenetics, the layer of chemical modifications that control how actively genes are read without changing the underlying DNA sequence. Researchers have found distinct epigenetic patterns in people with APS, particularly in how certain genes are methylated. In patients with APS, the promoter region of the gene for the inflammatory molecule IL-8 showed reduced methylation, meaning the gene was more active. At the same time, the tissue factor gene, which plays a role in initiating the clotting cascade, also showed methylation changes that increased its expression. When researchers treated cells in the lab with anti-beta-2-glycoprotein I antibodies, they could reproduce these same methylation shifts, suggesting that the antibodies themselves may drive epigenetic changes that worsen inflammation and clotting.¹⁷

A genome-wide methylation study in neutrophils, a type of white blood cell heavily involved in clot formation, found dozens of sites where methylation differed between APS patients and healthy controls. Among the genes affected were some associated with pregnancy biology, which is intriguing given that pregnancy complications are a hallmark of the syndrome.¹⁸ Whether these epigenetic changes are heritable across generations remains unclear. Some epigenetic marks can be passed down, but the field is still young, and there are no definitive studies showing that APS-related epigenetic patterns transfer meaningfully from parent to child.

Antibodies Crossing the Placenta

There is one scenario where a parent’s APS directly affects a newborn, but it is not genetic inheritance. Mothers with APS can transfer antiphospholipid antibodies to their babies through the placenta during pregnancy. Studies have shown that babies born to mothers with APS have elevated levels of IgG anticardiolipin antibodies at birth, with titers that track the mother’s antibody concentration. However, these maternal antibodies gradually decline over the first few months of life and are typically undetectable by six months.¹⁹

This temporary antibody transfer does not mean the child has APS or will develop it. The presence of these antibodies in a newborn reflects the mother’s immune status, not the baby’s own immune system. Once the maternal antibodies clear, the child’s risk of APS depends on their own genetic makeup and future environmental exposures, not on the antibodies they briefly carried.

Why APS Is More Common in Women

APS, like many autoimmune conditions, affects women far more often than men. The female-to-male ratio has been reported as high as 9 to 1 for antiphospholipid antibody syndrome.²⁰ One leading explanation involves X chromosome dosage. Women have two X chromosomes, and while one is normally silenced in each cell, incomplete silencing can lead to higher expression of certain immune-related genes located on the X chromosome. This higher gene dosage may push the immune system toward overactivity. Hormonal factors, particularly estrogen’s effects on immune cell behavior, also likely contribute. The sex disparity in APS is not itself a genetic inheritance pattern, but it does mean that women in families with autoimmune tendencies may face a disproportionate share of the risk.

Catastrophic APS and Emerging Genetic Discoveries

A rare but devastating form of the disease, catastrophic APS (CAPS), involves widespread clotting in multiple organs simultaneously and can be fatal. Recent research has identified a genetic and epigenetic marker that may distinguish CAPS from the more common forms of APS. Deficiency in a protein called CR1, caused by either genetic variants or epigenetic silencing of the CR1 gene, appears to be a potential hallmark of catastrophic disease. The finding is especially interesting because CR1 deficiency also predicted a response to treatment with complement inhibitors, a class of drugs that block part of the inflammatory cascade.²¹ This is early-stage research, but it hints at a future where genetic testing could help identify which patients are at risk for the most severe form of APS and guide treatment choices accordingly.

Should Family Members Be Tested?

Given the genetic component of APS, it is reasonable to wonder whether first-degree relatives of someone with the syndrome should be screened for antiphospholipid antibodies. Current guidelines do not recommend routine screening of asymptomatic family members, and the family study described earlier illustrates why: having the antibodies without symptoms is common, and a positive test in someone who feels perfectly healthy can create anxiety without a clear path of action. Antiphospholipid antibodies can be found transiently in healthy people after infections and may never lead to clinical disease.

That said, awareness matters. If you have a close relative with APS or another autoimmune disease and you experience an unexplained blood clot, recurrent pregnancy losses, or other suggestive symptoms, that family history is important context for your doctor. It should lower the threshold for testing and prompt consideration of APS in the workup. For pediatric patients, the overlap of inherited clotting variants with antiphospholipid antibodies has been linked to serious events like childhood stroke, making a thorough evaluation especially important when symptoms arise in a young person with a relevant family background.¹⁵

Pediatric APS and Recurrence

APS in children is less commonly discussed but not as rare as you might expect. When it does occur, it tends to be persistent. In one retrospective series of pediatric patients, about 40 percent with primary APS and 45 percent with secondary APS experienced recurrent thrombotic events. Two-thirds of the children in the study also had “non-criteria” features of APS, meaning symptoms like low platelet counts, autoimmune anemia, and a mottled skin pattern called livedo reticularis that are associated with the syndrome but are not included in the formal diagnostic criteria.²² Whether these children had identifiable inherited risk factors was not the primary focus of that study, but the high recurrence rate underscores that APS diagnosed in childhood tends to be a lifelong condition requiring ongoing management, regardless of whether a genetic cause can be pinpointed.